Clinical trials: SARCOIDOSIS
Pulmonary Sarcoidosis
Study of Intravenous ATYR1923 (Efzofitimod) for Pulmonary Sarcoidosis
This randomized, double-blind, placebo matched to efzofitimod-controlled, study will evaluate the safety, tolerability, immunogenicity, pharmacokinetic (PK), and preliminary efficacy of multiple ascending doses of IV efzofitimod…
- Trial name
- NCT03824392
- Where
- 15 sites in United States
- Volunteers
- 37 people
- Sponsor
- aTyr Pharma, Inc.
Sarcoidosis
Impact of Chemokine Receptor 5 (CCR5) Inhibition on Sarcoidosis Immunophenotypes
The study hypothesizes that inhibition of the receptor CCR5 by maraviroc will diminish inflammation in patients with sarcoidosis.
- Trial name
- GRADS (NCT02134717)
- Testing
- all subjects will receive maraviroc 300mg orally twice a day for 6 weeks, Bronchoscopy with bronchoalveolar lavage, venipunctures
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Kevin F. Gibson
Sarcoidosis
Trial of Antimycobacterial Therapy in Sarcoidosis
Growing research from independent laboratories provide an association between mycobacteria and sarcoidosis. More recent immunologic and molecular studies demonstrate immune responses to mycobacteria virulence factors.
- Trial name
- CLEAR (NCT01074554)
- Testing
- Antibiotic Regimen
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Vanderbilt University
Ocular Sarcoidosis, Panuveitis
Ocular Sarcoidosis Open Label Trial of ACTHAR Gel
Treatment with ACTHAR Gel will result in a reduction of ocular inflammation in patients with active ocular sarcoidosis that requires systemic immunosuppressant therapy (hypothesis)
- Conditions
- Ocular Sarcoidosis, Panuveitis, Anterior Uveitis
- Trial name
- NCT02725177
- Testing
- Repository Corticotropin Injection, Repository Corticotropin Injection -Treatment Extension
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- The Cleveland Clinic
Sarcoidosis-associated Pulmonary Hypertension
A Study in Participants With Sarcoidosis-associated Pulmonary Hypertension (SAPH) to Assess the Efficacy and Safety of Oral Selexipag
Oral selexipag is commercially available in several countries for the treatment of a particular group of pulmonary hypertension (PH) called pulmonary arterial hypertension (PAH).
- Trial name
- SPHINX (NCT03942211)
- Testing
- Selexipag
- Where
- 38 sites in United States, Belgium and 8 more
- Volunteers
- 10 people
- Sponsor
- Actelion
Pulmonary Sarcoidosis
Study of Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Patients With Pulmonary Sarcoidosis
The purpose of this study is to assess if ACZ885 will improve lung function in association with reduction of tissue inflammation in patients with chronic sarcoidosis.
- Trial name
- NCT02888080
- Testing
- ACZ885
- Where
- 8 sites in United States, Germany and 1 more
- Volunteers
- 40 people
- Sponsor
- Novartis Pharmaceuticals
Sarcoidosis
Nicotine Treatment for Pulmonary Sarcoidosis: A Clinical Trial Pilot Study
The purpose of this study is to determine if nicotine treatment is beneficial for the treatment of sarcoidosis. Sarcoidosis is a disease of unknown cause that leads to inflammation. This disease affects your body's organs.
- Trial name
- NCT02265874
- Testing
- Habitrol
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Ohio State University
Pulmonary Sarcoidosis
The Effect of N-Acetyl-L-Cysteine, on Inflammatory and Oxidative Stress Markers in Pulmonary Sarcoidosis
This is a pilot study investigating the effect of an antioxidant, N-Acetyl-L-Cysteine (NAC), on inflammation and oxidative stress in sarcoidosis.
- Trial name
- NCT01587001
- Testing
- N-acetyl-cysteine
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- National Jewish Health
Sarcoidosis, Fatigue
SPARC Smartphone Application for the Management of Sarcoidosis-Associated Fatigue
Fatigue is a pervasive and disabling symptom in sarcoidosis with limited treatment options. There is a significant association between heightened stress and sarcoidosis-associated fatigue.
- Trial name
- SPARC (NCT05230693)
- Testing
- Sarcoidosis Patient Assessment and Resource Companion App, Enhanced Standard Care
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Medical University of South Carolina
Neuropathy of Sarcoidosis
Study of Efficacy of ARA 290 on Corneal Nerve Fiber Density and Neuropathic Symptoms of Subjects With Sarcoidosis
The purpose of this study is to determine whether ARA 290, a new class of compound, is effective in the treatment of the neuropathic symptoms of sarcoidosis.
- Trial name
- NCT02039687
- Testing
- ARA 290
- Where
- 2 sites in United States, Netherlands
- Volunteers
- 64 people
- Sponsor
- Araim Pharmaceuticals, Inc.
Sarcoidosis
Hematopoietic Stem Cell Support in Patients With Refractory Sarcoidosis
Sarcoidosis is a disease believed to be due to immune cells, cells which normally protect the body, but are now attacking lungs, heart, nerves, or other organs or systems within the body.
- Trial name
- NCT00282438
- Testing
- Autologous hematopoietic stem cell transplantation, Allogeneic stem cell transplantation
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Northwestern University
Sarcoidosis
Trial of Adalimumab in Progressive Sarcoidosis
Sarcoidosis is a rare disease that can affect any organ in the body. It is characterized by the buildup of immune-system (fights off infection in the body) cells in organs.
- Trial name
- NCT00311246
- Testing
- Adalimumab
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Chicago
Hepatic Sarcoidosis, Elevated Alkaline Phosphatase
Ursodeoxycholic Acid (UDCA) for Hepatic Sarcoidosis
This study aims to (1) evaluate efficacy of UDCA in improving liver function and quality of life; (2) monitor safety, tolerability of UDCA, as well as progression of hepatic sarcoidosis and liver disease, in patients diagnosed…
- Trial name
- NCT03602976
- Testing
- Ursodeoxycholic Acid
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Ethan Weinberg
Pulmonary Arterial Hypertension, Pulmonary Hypertension
Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) - LARIAT
This study assesses the safety and efficacy of bardoxolone methyl relative to placebo in patients with pulmonary hypertension to determine the recommended dose range, evaluate the change from baseline in 6-minute walk distance…
- Conditions
- Pulmonary Arterial Hypertension, Pulmonary Hypertension, Interstitial Lung Disease, Idiopathic Interstitial Pneumonia
- Trial name
- NCT02036970
- Testing
- Bardoxolone methyl
- Where
- 32 sites in United States, Germany
- Volunteers
- 166 people
- Sponsor
- Biogen
Cardiac Sarcoidosis, Myocardial Inflammation
18F-FSPG PET/MRI or PET/CT Imaging of Cardiac Sarcoidosis or Inflammation
The investigators will evaluate the detection of cardiac sarcoidosis or inflammation using 18F-FSPG PET/MRI (or PET/CT for participants with metal implants).
- Trial name
- NCT03103490
- Testing
- 18F-FSPG
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Stanford University
Sarcoidosis
A Study to Evaluate the Safety and Effectiveness of Ustekinumab or Golimumab Administered Subcutaneously (SC) in Patients With Sarcoidosis
This study tests the safety and effectiveness of ustekinumab or golimumab compared to placebo (placebo looks like the drugs being studied, but has no active ingredients).
- Trial name
- NCT00955279
- Testing
- Golimumab, Ustekinumab
- Where
- 53 sites in United States, Belgium and 7 more
- Volunteers
- 173 people
- Sponsor
- Centocor, Inc.
Cardiac Sarcoidosis
Non-Invasive Characterization in Cardiac Sarcoidosis
In a study of Cardiac sarcoidosis, a serious heart condition, a radiotracer is being used to examine inflammation.
- Trial name
- NCT02017522
- Testing
- 11C-PBR PET
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Michigan
Sarcoidosis
Use of CXCL9 as a Biomarker of Acthar Efficacy
The objective is this study is to test whether use of Acthar gel in the context of sarcoidosis will lead to improved symptoms and lung function and correlate with decreased levels of predictive blood biomarkers, like chemokine…
- Trial name
- Acthar (NCT02523092)
- Testing
- Acthar gel
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of California, San Francisco
Cardiac Sarcoidosis
Interleukin-1 Blockade for Treatment of Cardiac Sarcoidosis
Sarcoidosis is a heterogeneous disorder of unknown etiology whose signature lesions are granulomatous inflammatory infiltrates in involved tissues. Tissue commonly affected are lungs, skin, eyes, lymph nodes and the heart.
- Trial name
- MAGiC-ART (NCT04017936)
- Testing
- Anakinra
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- Virginia Commonwealth University
Sarcoidosis; Antimycobacterial Therapy
Phase II Investigation of Antimycobacterial Therapy on Progressive, Pulmonary Sarcoidosis
The primary purpose of this study is to investigate the efficacy and safety of oral antimycobacterial therapy in patients with confirmed progressive pulmonary sarcoidosis.
- Trial name
- NCT02024555
- Testing
- Levofloxacin, Ethambutol, Azithromycin
- Where
- 6 sites in United States
- Volunteers
- 97 people
- Sponsor
- Vanderbilt University